Profile data is unavailable for this security.
About the company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD-67.33k
- Incorporated2024
- Employees17.00
- LocationTevogen Bio Holdings Inc15 Independence Boulevard, Suite 410WARREN 07059United StatesUSA
- Phone+1 (646) 807-8832
- Fax+1 (302) 655-5049
Mergers & acquisitions
Acquired company | TVGN:NMQ since announced | Transaction value |
---|---|---|
Tevogen Bio Inc | -92.24% | 1.41bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 136.99m | 28.00 | -- | 3.22 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
Seres Therapeutics Inc | 126.85m | -82.68m | 140.00m | 233.00 | -- | -- | -- | 1.10 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
Elite Pharmaceuticals Inc | 47.32m | 15.55m | 141.47m | 53.00 | 9.11 | 3.05 | 8.37 | 2.99 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
I-Mab ADR | 3.83m | -203.06m | 143.16m | 220.00 | -- | 0.6001 | -- | 37.38 | -2.44 | -2.44 | 0.046 | 2.95 | 0.0083 | -- | -- | 17,408.26 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
Rapt Therapeutics Inc | 0.00 | -118.05m | 144.07m | 126.00 | -- | 1.10 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
Biostem Technologies Inc | 16.69m | -7.86m | 146.09m | 67.00 | -- | -- | -- | 8.76 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
Syros Pharmaceuticals Inc | 6.98m | -144.49m | 146.47m | 68.00 | -- | 9.73 | -- | 20.98 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Tevogen Bio Holdings Inc | 0.00 | -67.33k | 146.51m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
Bioatla Inc | 0.00 | -119.24m | 149.13m | 65.00 | -- | 3.00 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Repare Therapeutics Inc | 97.86m | -45.69m | 149.83m | 179.00 | -- | 0.6404 | -- | 1.53 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Sagimet Biosciences Inc | 2.00m | -27.88m | 151.60m | 10.00 | -- | 1.19 | -- | 75.80 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
CytomX Therapeutics Inc | 119.18m | 16.53m | 155.84m | 120.00 | 10.11 | -- | 8.39 | 1.31 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
ProQR Therapeutics NV | 14.65m | -29.17m | 156.20m | 157.00 | -- | 4.28 | -- | 10.66 | -0.3592 | -0.3592 | 0.1805 | 0.4491 | 0.0957 | -- | -- | 93,341.77 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
Scilex Holding Co | 47.05m | -160.60m | 157.64m | 106.00 | -- | -- | -- | 3.35 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Portland Global Advisors LLCas of 31 Mar 2024 | 5.78m | 3.51% |
Harraden Circle Investments LLCas of 10 Jan 2024 | 838.97k | 0.51% |
Meteora Capital LLCas of 31 Dec 2023 | 505.67k | 0.31% |
Glazer Capital LLCas of 31 Dec 2023 | 149.53k | 0.09% |
Centiva Capital LPas of 31 Dec 2023 | 100.00k | 0.06% |
Westchester Capital Management LLCas of 31 Dec 2023 | 99.95k | 0.06% |
Koch Industries, Inc. (Investment Management)as of 31 Dec 2023 | 50.00k | 0.03% |
Jackson National Asset Management LLCas of 31 Dec 2023 | 4.12k | 0.00% |
Clear Street LLCas of 31 Dec 2023 | 600.00 | 0.00% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 30.00 | 0.00% |